Cargando…

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America

Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheinberg, Morton, Pineda, Carlos, Castañeda-Hernández, Gilberto, Zarbá, Juan José, Damião, Aderson, Arantes Jr, Luiz H, Jacobs, Ira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152448/ https://www.ncbi.nlm.nih.gov/pubmed/30156950 http://dx.doi.org/10.1080/19420862.2018.1484977

Ejemplares similares

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2019)

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey
por: Castañeda‐Hernández, Gilberto, et al.
Publicado: (2019)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view
por: Pineda, Carlos, et al.
Publicado: (2015)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
por: Cook, John W., et al.
Publicado: (2019)

Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America
por: Giugliani, Roberto, et al.
Publicado: (2014)

Latin America : diplomacy and reality
por: Berle, Adolf A., Jr., 1895-1971
Publicado: (1962)

Biosimilars: potential implications for clinicians
por: Eleryan, Misty G, et al.
Publicado: (2016)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
por: Steinberg, Judith, et al.
Publicado: (2019)

Integration of artificial intelligence and precision oncology in Latin America
por: Sussman, Liliana, et al.
Publicado: (2022)

Editorial: Global excellence in oncology: Latin America 2022
por: Camacho, Javier, et al.
Publicado: (2022)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
por: Scheinberg, Morton, et al.
Publicado: (2014)

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)
por: Lara Gongora, Aline B., et al.
Publicado: (2021)

The status of cryptococcosis in Latin America
por: Firacative, Carolina, et al.
Publicado: (2018)

Quality Indicators in Pediatric Palliative Care: Considerations for Latin America
por: Zuniga-Villanueva, Gregorio, et al.
Publicado: (2021)

Can biosimilars help achieve the goals of US health care reform?
por: Boccia, Ralph, et al.
Publicado: (2017)

Precision oncology in Latin America: current situation, challenges and perspectives
por: Calderón-Aparicio, Ali, et al.
Publicado: (2019)

Health in the Courts of Latin America
por: Ferraz, Octávio Luiz Motta
Publicado: (2018)

Chronobiology in Latin America: XIII Latin American Symposium on Chronobiology
por: Menna-Barreto, Luiz
Publicado: (2016)

American Society of Clinical Oncology–Sponsored Oncology Student Interest Groups in Latin America
por: Anampa-Guzmán, Andrea, et al.
Publicado: (2020)

Pharmacovigilance Considerations for Biosimilars in the USA
por: Grampp, Gustavo, et al.
Publicado: (2015)

Clinical considerations for biosimilar antibodies
por: Mellstedt, Håkan
Publicado: (2013)

Statistical Primer on Biosimilar Clinical Development
por: Isakov, Leah, et al.
Publicado: (2016)

Radiation Oncology Residency Training in Latin America: A Call to Attention
por: Li, Benjamin, et al.
Publicado: (2022)

Robotics Research Growth in Latin America: Topical Collection on LARS 2020
por: Drews-Jr., Paulo L. J., et al.
Publicado: (2023)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Latin America /
por: Goodwin, Paul B., 1942-
Publicado: (2000)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nf5n4189ntcaonts38ilsf2j4l